MAP2K7 and neoplasm: In multivariate analysis, the only two factors that predicted a superior OS after referral to the Phase I clinic in the mutBRAF group were treatment with any RAF/MEK targeting agents (HR 0.16, 95% CI, 0.03–0.89, p = 0.037) and any decrease in tumor size (RECIST measurement) on any phase I trial (HR 0.07, 95% CI, 0.015–0.35, p = 0.001) (Figure 4).